Company Description
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries.
In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures.
It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001.
LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 1983 |
| IPO Date | Oct 19, 2006 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 664 |
| CEO | George LeMaitre |
Contact Details
Address: 63 Second Avenue Burlington, Massachusetts 01803 United States | |
| Phone | 781 221 2266 |
| Website | lemaitre.com |
Stock Details
| Ticker Symbol | LMAT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001158895 |
| CUSIP Number | 525558201 |
| ISIN Number | US5255582018 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| George W. LeMaitre | Chairman and Chief Executive Officer |
| David B. Roberts | President and Director |
| Trent G. Kamke | Senior Vice President of Operations |
| Dr. George D. LeMaitre | Founder and Chairman of Scientific Advisory Board |
| Kimberly L. Cieslak | Vice President of Marketing |
| Daniel J. Mumford | Senior Director of Human Resources |
| Jonathan W. Ngau | Senior Vice President of Information Technology |
| Maik D. Helmers | Senior Vice President of Sales ? Central Europe |
| Ryan H. Connelly | Senior Vice President of Advanced Manufacturing Engineering |
| Andrew Hodgkinson | Senior Vice President of Clinical, Regulatory and Quality Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | 144 | Filing |
| Mar 12, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 8-K | Current Report |